The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home

Physiogenex provides preclinical CRO services and expertise with a 15-year expertise in evaluating drugs targeting obesity/diabetes, NASH/fibrosis, diabetic nephropathy & cardiovascular complications, dyslipidemia/atherosclerosis.

See our most popular models:

All our models are provided with benchmarks and validated in vivo experiments, biochemical assays and histology analysis/NAS scoring. Frozen/fixed biological samples from our models can be shipped to test your biomarkers and therapeutic target.

Contact us to start a collaboration

PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

 

Our services to evaluate your drugs targeting

DIABETES Insulin resistance OBESITY
LIVER DISEASES NAFLD Hepatic steatosis to fibrosis
Animal models from basic to predictive in-house models
Experimental platform From gold-standard to innovative assays
Scientific expertise and translational vision